NO20033782L - Farmasöytisk blanding som omfatter en fast dispersjon av hydroksypropylmetylcelluloseftalatpolymer - Google Patents

Farmasöytisk blanding som omfatter en fast dispersjon av hydroksypropylmetylcelluloseftalatpolymer

Info

Publication number
NO20033782L
NO20033782L NO20033782A NO20033782A NO20033782L NO 20033782 L NO20033782 L NO 20033782L NO 20033782 A NO20033782 A NO 20033782A NO 20033782 A NO20033782 A NO 20033782A NO 20033782 L NO20033782 L NO 20033782L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
methyl cellulose
solid dispersion
hydroxypropyl methyl
cellulose phthalate
Prior art date
Application number
NO20033782A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033782D0 (no
Inventor
Nicola Bateman
Julie Cahill
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20033782D0 publication Critical patent/NO20033782D0/no
Publication of NO20033782L publication Critical patent/NO20033782L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20033782A 2001-02-27 2003-08-26 Farmasöytisk blanding som omfatter en fast dispersjon av hydroksypropylmetylcelluloseftalatpolymer NO20033782L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0104752.1A GB0104752D0 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions
PCT/SE2002/000327 WO2002067904A1 (en) 2001-02-27 2002-02-25 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer

Publications (2)

Publication Number Publication Date
NO20033782D0 NO20033782D0 (no) 2003-08-26
NO20033782L true NO20033782L (no) 2003-08-26

Family

ID=9909545

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033782A NO20033782L (no) 2001-02-27 2003-08-26 Farmasöytisk blanding som omfatter en fast dispersjon av hydroksypropylmetylcelluloseftalatpolymer

Country Status (14)

Country Link
US (1) US20040138231A1 (enExample)
EP (1) EP1365746A1 (enExample)
JP (1) JP2004527489A (enExample)
KR (1) KR20040011469A (enExample)
CN (1) CN1533268A (enExample)
BR (1) BR0206960A (enExample)
CA (1) CA2435815A1 (enExample)
GB (1) GB0104752D0 (enExample)
IL (1) IL156830A0 (enExample)
MX (1) MXPA03006746A (enExample)
NO (1) NO20033782L (enExample)
NZ (1) NZ527080A (enExample)
WO (1) WO2002067904A1 (enExample)
ZA (1) ZA200305386B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
KR100531612B1 (ko) * 2003-08-12 2005-11-28 경동제약 주식회사 지속성 탐스로신 정제의 제조방법 및 그에 따른 지속성탐스로신 정제
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2025078941A1 (en) * 2023-10-09 2025-04-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of pirtobrutinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
TW212139B (enExample) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
DE69428707T2 (de) * 1993-08-20 2002-07-11 Nippon Shinyaku Co., Ltd. Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
CN1133634C (zh) * 1998-05-02 2004-01-07 阿斯特拉曾尼卡有限公司 抑制因子Xa的杂环衍生物
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物

Also Published As

Publication number Publication date
ZA200305386B (en) 2004-10-11
NZ527080A (en) 2005-02-25
KR20040011469A (ko) 2004-02-05
GB0104752D0 (en) 2001-04-18
EP1365746A1 (en) 2003-12-03
US20040138231A1 (en) 2004-07-15
MXPA03006746A (es) 2003-10-24
JP2004527489A (ja) 2004-09-09
NO20033782D0 (no) 2003-08-26
WO2002067904A1 (en) 2002-09-06
CA2435815A1 (en) 2002-09-06
BR0206960A (pt) 2004-03-09
CN1533268A (zh) 2004-09-29
IL156830A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
NO20033782D0 (no) Farmasöytisk blanding som omfatter en fast dispersjon av hydroksypropylmetylcelluloseftalatpolymer
NO20043866L (no) Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
NO20014893L (no) Farmasoytiske sammensetninger av erythropoietin
DK1311285T3 (da) Flydende farmaceutisk præparat, som omfatter et erythropoietinderivat
NO20035729D0 (no) Piperidinderivater som er nyttige som modulatorer av kemokin- reseptor-aktivitet
NO20035157D0 (no) Lungeadministrering av kjemisk modifisert insulin
NO20032181D0 (no) Anvendelse av CCI-779 som et antineoplastisk middel
PT1439829E (pt) Medicamento contendo 3-(3-dimetilamino-1-etil-2-metilpropil)-fenol proporcionando libertacao retardada da substancia activa
NO20012248L (no) Farmasöytisk preparat av moksifloksacin
NO20035438D0 (no) Farmas degree ytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
NO20013205D0 (no) Farmasöytiske formuleringer i hydroksypropylmetylcellulosekapsler
DE60110666D1 (de) Feste Zubereitung enthaltend niedersubstituierte Hydroxypropylcellulose und Herstellungsverfahren
NO20015530L (no) Fremgangsmåte til fremstilling av inherente mikrobedrepende polymeroverflater
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
AU2002346457A1 (en) Pharmaceutical formulations comprising indolinone derivatives
NO20021866L (no) Ciclesonid-inneholdende vandig farmasoytisk blanding
WO2006115712A3 (en) Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability
NO995945L (no) Nye forbindelser
EP1447084A4 (en) FREEZE-DRIED PHARMACEUTICAL PREPARATION
NO20043007L (no) Farmasoytisk suspensjon for oral administrering
AU2003227612A1 (en) Microcapsules for the production of storage-stable unsaturated polymer compositions
NO20042202L (no) Fremgangsmate for fremstilling av asymmetriske karotenoider
NO20004816D0 (no) Ny farmasøytisk formulering

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application